(GAS) and physician GAS (6) , RA health assessment questionnaire (RA-HAQ), and RA quality of life scale (RA-QoL) (7) . A score of DAS28 of <3.2 was accepted as mild RA, scores between 3.2 and 5.1 as moderate RA, and scores of >5.1 as severe RA (8) . A HAQ cut-off value of ≥1.5 is accepted as signifying an unsatisfactory functional state (9) .
The laboratory assessment of disease activity included erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
Ankylosing spondylitis
The modified New York criteria were used for the diagnosis of AS (10) . The AS forms included age, sex, duration of the disease, drugs used for the treatment of AS, and clinical parameters of disease activity including VAS, Schober test, and chest expansion values. Other assessments included the Bath Ankylosing Spondylitis Functional Index (BASFI) (11) , Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (12) , patient GAS (13), physician GAS (13), AS-HAQ (14) , and AS-QoL (13) . The laboratory assessment of disease activity included ESR and CRP levels. A BASDAI score of ≥4 was accepted as signifying active disease (9).
Statistical analysis
Nominal data were expressed as mean ± standard deviation (SD). Categorical variables were presented as numbers and percentages.
Results
Demographic characteristics of the patients with RA (n = 45) and AS (n = 45) are shown in Table 1 . The maleto-female ratio was 1:3.5 for RA patients and 3.1:1.4 for AS patients. The mean age for the patients followed with the diagnosis of RA was much higher (53.67 ± 11.6 years, median: 51 years) compared to patients with AS (34.13 ± 10.21 years, median: 31 years). The mean duration of the disease for RA patients was 6.12 ± 6.4 years, the median was 4 years, and the range was 1 month to 30 years. For the patients with AS, the mean duration of the disease was 6.1 ± 5.2 years, the median was 5 years, and the range was 1 month to 20 years.
Rheumatoid arthritis
Clinical disease activity for RA was assessed using patient reported morning stiffness (in minutes), VAS, tender joints and swollen joints on physical examination, and laboratory findings including ESR and CRP. DAS28 scores were calculated as described previously (5) ( Table 2 ).
The mean duration of morning stiffness was 13.84 ± 28.9 min (median: 1 min, range: 0-120 min). On physical examination, the mean number of tender joints was 8.4 ± 8.6 (median: 6, range: 0-28) and the mean number of swollen joints was 1.9 ± 2.7 (median: 1, range: 0-13). In patients with RA, the mean ESR was 27.82 ± 11.9 mm/h and the median was 21.5 mm/h, and 25 patients (56%) had ESR values of over 20 mm/h at the time of data collection. The mean CRP level was 10.32 ± 12.3 mg/L and the median was 5 mg/L, and 20 patients (44%) had CRP of >5 mg/L at the time of data collection. The mean DAS28 score was 4.3 ± 1.6 (median: 4.4, range: 1.52-7.78) ( Table 2 ). According to the DAS28, 27% of RA patients had mild disease, 44% had moderate, and 29% had severe.
Ankylosing spondylitis
Clinical disease activity for AS was assessed on physical examination using chest expansion measurement, Schober test, VAS, and BASDAI, and physical functioning state was assessed by BASFI scores as described previously (11, 12) .
The mean chest expansion was 5.33 ± 1.8 cm (median: 5 cm, range: 1.5-9.0 cm). The mean Schober test result was 4.7 ± 1.5 cm (median: 4.5 cm, range: 1-8 cm). The mean BASDAI score was 4.6 ± 2.3 (median: 4.6, range: 0.8-9.0), and 64% of patients had active disease based on BASDAI scores. The mean BASFI score was 3.29 ± 2.9 (median: 2.5, range: 0-12.1). In patients with AS, the mean ESR was 16.54 ± 18.6 mm/h and the median was 9 mm/h, and 7 patients (16%) had ESR values of >20 mm/h at the time of data collection. The mean CRP level was 10.07 ± 19.9 mg/L and the median was 3 mg/L, and 7 patients (16%) had CRP of >5 mg/L at the time of data collection (Table 3) .
Physician and patient GAS
The severity of disease for both RA and AS was evaluated using physician GAS and patient GAS as described elsewhere (6,12,13) ( Table 4 ). For RA, the mean physician GAS was 4.11 ± 2.9 (median: 5, range: 0-8) and the mean patient GAS was 4.64 ± 2.4 (median: 5, range: 0-10), and for AS, the physician GAS was 4.8 ± 2.8 (median: 5, range: 0-10 ) and the mean patient GAS was 4.9 ± 3.1 (median: 5, range: 0-10).
HAQ and QoL
The quality of life for RA and AS patients was evaluated using HAQ and QoL scales (Table 4 ). For patients with RA, the mean HAQ score was 13.04 ± 12.9 (median: 10, range: 0-51) and the mean QoL score was 14.13 ± 9.1 (median: 15, range: 0-30). In RA patients, 25% had a HAQ score of <1.5 (satisfactory functional state). For patients with AS, the mean HAQ score was 3.64 ± 2.2 (median: 3, range: 0-11) and the mean QoL score was 8.91 ± 5.3 (median: 10, range: 0-18). In AS patients, 16% had a HAQ score of <1.5 (satisfactory functional state).
Treatment
The drugs used in patients with RA are listed in Table 5 . A high percentage (31.1%) of patients with RA were only on nonsteroidal antiinflammatory drugs (NSAIDs). Only a small percentage was taking a single disease-modifying antirheumatic drug (DMARD), whereas 13.3% were taking combined DMARDs. However, the highest percentage of patients (35.6%) were treated with biological agents.
For AS patients, the treatment regimens used are shown in Table 6 . Twenty-four percent of patients with AS were treated with NSAIDs and another 24% with an NSAID-sulfasalazine combination. About 22% of patients with AS were receiving biological agents and 13% were not on any medication at the time of data collection.
Discussion
In this study, the clinical and laboratory characteristics of the 2 most common rheumatic diseases, namely RA and AS, were analyzed. There are a few studies reported from Turkey about the clinical characteristics of RA and AS (15) (16) (17) (18) (19) . Since the sample size of this study is small, rather than being an epidemiologic study, it represents the data of a small sample of patients in an urban area of Turkey treated in a tertiary care center and forms a descriptive study.
In this study, the male-to-female ratio for RA was 1:3.5 and for AS was 3.1:1.4, both very similar to the reported epidemiologic studies worldwide (1,3) . In our crosssectional study, the mean age of patients with RA was much higher (53.67 ± 11.6 years) compared to patients with AS (34.13 ± 10.21 years), and this is consistent with the natural course of the disease and the fact that RA presents much later compared to AS in adult populations (8) .
The activity of the disease can be assessed by using different measures including the DAS28 for RA and the Biologic agent-DMARD combination 4 8.9
*: Nonsteroidal antiinflammatory drugs, **: disease-modifying antirheumatic drugs. (19) . According to the HAQ scoring, which is used to evaluate the functional state of the patients with RA, only 25% were functionally satisfactory. This finding was in parallel to DAS28 scoring in our study.
In patients with AS, according to the BASDAI, 64% of patients had active disease. This percentage is similar to that in a previous study done in Turkey (19) . In AS patients, only 16% of the patients had a HAQ score of <1.5 (satisfactory functional state). Although AS patients seem to have less severe disease activity and better functional states compared to RA patients, it still seems to be quite severe disease in most cases in our study. Since this study was done in a tertiary care center with referrals of the most severe cases, this high percentage of severe disease affecting the functional state of the majority of patients is not surprising.
The treatment regimen used in RA in this crosssectional study at the time of data collection included NSAIDs, DMARDs, biologic agents, and various combinations of these. In RA, the most common treatment used was biological agents at a rate of 35.6%, followed by NSAIDs alone. The use of combined DMARDs was 6 times more common compared to the use of a single DMARD. Previous studies show that the most common treatment prescribed is DMARDs, at a rate of 72%-93% (19, 20) . The discrepancy between our data and the data in the literature may be due to biological agents being more widely available in our country in the past 10 years. Another finding noted was that the percentage of patients on NSAIDs alone seems to be quite high, which may be due to the fact that the patients who are on NSAIDs are more frequently referred to our tertiary center due to inadequate control of the disease with NSAIDs alone.
In our study, the most common treatments prescribed for AS patients included NSAIDs alone and the NSAIDsulfasalazine combination (24.4% each). In contrast to a previous study in Turkey (19) , none of our patients were on methotrexate treatment since recent studies have shown that it is ineffective in modifying the course of the disease (21) . The second most common treatment regimen was biological agents at 22.2%. About 13% of the patients were not on any medications due to either noncompliance/ patient preference or due to inactive disease.
In conclusion, in our tertiary care center, the majority of patients with RA and AS had active disease with unsatisfactory functional state. Investigating the reasons for the high rate of active disease in a tertiary care center is worthwhile, and this would be helpful in defining new and better strategies in the control of these diseases.
